Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01536938 · ClinicalTrials.gov registry record · Phase 2
LEO 90100 in the Treatment of Psoriasis Vulgaris
A Phase 2 study, sponsored by LEO Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 303
- Enrollment target
NCT01536938 is a Phase 2 study that has completed, run by LEO Pharma. The registered enrollment target is 303 participants.
The verdict
NCT01536938, a Phase 2 study, has completed, sponsored by LEO Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 303 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate whether LEO 90100, calcipotriol and betamethasone are effective in the treatment of psoriasis vulgaris.
Interventions
- DRUG LEO 90100
- DRUG Betamethasone
- DRUG Calcipotriol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 303 participants |
| Start Date | 2012-05 |
| Est. Completion | 2012-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01536938
The ClinicalTrials.gov registry entry for NCT01536938 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 303 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LEO Pharma, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which LEO 90100 is the first listed.
NCT01536938 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01536938 about?
NCT01536938 is a clinical study titled "LEO 90100 in the Treatment of Psoriasis Vulgaris". The purpose of this study is to investigate whether LEO 90100, calcipotriol and betamethasone are effective in the treatment of psoriasis vulgaris.
What is the current status of trial NCT01536938?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 303 participants. The study started on 2012-05. Estimated completion is 2012-11.
What interventions are being tested in trial NCT01536938?
The interventions under investigation include: LEO 90100 (DRUG), Betamethasone (DRUG), Calcipotriol (DRUG).
Who is sponsoring clinical trial NCT01536938?
This trial is sponsored by LEO Pharma, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.